Official ESCRS | European Society of Cataract & Refractive Surgeons
Vienna 2018 Delegate Registration Programme Exhibition Virtual Exhibition Satellites 2018 Survey

 

escrs app advert

Effect of oral digoxin use on corneal endothelium

Search Title by author or title

Session Details

Session Title: Cornea Miscellaneous

Session Date/Time: Monday 24/09/2018 | 16:30-18:00

Paper Time: 17:36

Venue: Room A3, Podium 3

First Author: : A.Ataç TURKEY

Co Author(s): :    S. Sul                    

Abstract Details

Purpose:

To determine the effect of digoxin which is a Na-K ATPase blocker on corneal morphological parameters

Setting:

Department of ophthalmology, Muğla Sıtkı Koçman University Faculty of Medicine

Methods:

46 eyes of 46 women were enrolled in this study. Group 1 consisted of 18 women who received oral digoxin due to heart failure at least 1 year. Blood digoxin levels were between normal therapeutic range (0.5-2ng/mL). Group 2 consisted of 28 aged and sex match healthy women. Patients with history of intraocular surgery and trauma, corneal dystrophy, pseudoexfoliation and diabetes were excluded. Corneal endothelial cell density (CD,cells/mm2), cell area (µm2), Polymegethism (CV) and pleomorphism (Hexagonality) were evaluated with non-contact specular microscopy and compared between two groups. Central corneal thickness (CCT) was evaluated with ultrasonic pachymeter.

Results:

Mean age was 75.3±4 in group 1 and 75.4±3 in group 2 (p=0.940). Mean CD was 2527±152/mm2 in group 1 and 2555±204/mm2 in group 2 (p=0.613). Mean cell area was 390±29 µm2 in group 1 and 399±40 µm2 in group 2 (p=0.451). CV (31±2% in group 1 and 30±5 % in group 2 respectively, p=0.612) and hexagonality (68.3±3% in group 1 and 69.6±3% in group 2 respecively, p=0.159) were similar between two groups. Mean CCT was 548±24 µ in group 1 and 546±26µ in group 2 (p=0.892).

Conclusions:

Digoxin use within the normal blood therapeutic levels seem to have no deleterious effect on corneal endothelial cell morphology.

Financial Disclosure:

-

Back to previous